|
1
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pollock PM, Harper UL, Hansen KS, Yudt LM,
Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J,
et al: High frequency of BRAF mutations in nevi. Nat Genet.
33:19–20. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Long GV, Menzies AM, Nagrial AM, Haydu LE,
Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA and
Kefford RF: Prognostic and clinicopathologic associations of
oncogenic BRAF in metastatic melanoma. J Clin Oncol. 29:1239–1246.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chappé C, Padovani L, Scavarda D, Forest
F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin
C, et al: Dysembryoplastic neuroepithelial tumors share with
pleomorphic xanthoastrocytomas and gangliogliomas
BRAFV600E mutation and expression. Brain Pathol.
23:574–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dougherty MJ, Santi M, Brose MS, Ma C,
Resnick AC, Sievert AJ, Storm PB and Biegel JA: Activating
mutations in BRAF characterize a spectrum of pediatric low-grade
gliomas. Neuro Oncol. 12:621–630. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schindler G, Capper D, Meyer J, Janzarik
W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C,
Hasselblatt M, et al: Analysis of BRAF V600E mutation in 1,320
nervous system tumors reveals high mutation frequencies in
pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar
pilocytic astrocytoma. Acta Neuropathol. 121:397–405. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prabowo AS, Iyer AM, Veersema TJ, Anink
JJ, Schouten-van Meeteren AY, Spliet WG, van Rijen PC, Ferrier CH,
Capper D, Thom M, et al: BRAF V600E mutation is associated with
mTOR signaling activation in glioneuronal tumors. Brain Pathol.
24:52–66. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones DTW, Hutter B, Jäger N, Korshunov A,
Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, et
al: International Cancer Genome Consortium PedBrain Tumor Project:
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic
astrocytoma. Nat Genet. 45:927–932. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Wu G, Miller CP, Tatevossian RG,
Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, et
al: St. Jude Children's Research Hospital-Washington University
Pediatric Cancer Genome Project: Whole-genome sequencing identifies
genetic alterations in pediatric low-grade gliomas. Nat Genet.
45:602–612. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dias-Santagata D, Lam Q, Vernovsky K, Vena
N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon
AH, et al: BRAF V600E mutations are common in pleomorphic
xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS
One. 6:e179482011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ida CM, Vrana JA, Rodriguez FJ, Jentoft
ME, Caron AA, Jenkins SM and Giannini C: Immunohistochemistry is
highly sensitive and specific for detection of BRAF V600E mutation
in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun.
1:202013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koelsche C, Sahm F, Wöhrer A, Jeibmann A,
Schittenhelm J, Kohlhof P, Preusser M, Romeike B, Dohmen-Scheufler
H, Hartmann C, et al: BRAF-mutated pleomorphic xanthoastrocytoma is
associated with temporal location, reticulin fiber deposition and
CD34 expression. Brain Pathol. 24:221–229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schiffman JD, Hodgson JG, VandenBerg SR,
Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger
MS, et al: Oncogenic BRAF mutation with CDKN2A inactivation is
characteristic of a subset of pediatric malignant astrocytomas.
Cancer Res. 70:512–519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Broniscer A, Tatevossian RG, Sabin ND,
Klimo P Jr, Dalton J, Lee R, Gajjar A and Ellison DW: Clinical,
radiological, histological and molecular characteristics of
paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol.
40:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kleinschmidt-DeMasters BK, Aisner DL,
Birks DK and Foreman NK: Epithelioid GBMs show a high percentage of
BRAF V600E mutation. Am J Surg Pathol. 37:685–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Behling F, Barrantes-Freer A, Skardelly M,
Nieser M, Christians A, Stockhammer F, Rohde V, Tatagiba M,
Hartmann C, Stadelmann C, et al: Frequency of BRAF V600E mutations
in 969 central nervous system neoplasms. Diagn Pathol. 11:552016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aguilera D, Janss A, Mazewski C,
Castellino RC, Schniederjan M, Hayes L, Brahma B, Fogelgren L and
MacDonald TJ: Successful retreatment of a child with a refractory
brainstem ganglioglioma with vemurafenib. Pediatr Blood Cancer.
63:541–543. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bautista F, Paci A, Minard-Colin V, Dufour
C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D and Geoerger B:
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade
gliomas. Pediatr Blood Cancer. 61:1101–1103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
del Bufalo F, Carai A, Figà-Talamanca L,
Pettorini B, Mallucci C, Giangaspero F, Antonelli M, Badiali M, Moi
L, Bianco G, et al: Response of recurrent BRAFV600E mutated
ganglioglioma to Vemurafenib as single agent. J Transl Med.
12:3562014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rush S, Foreman N and Liu A: Brainstem
ganglioglioma successfully treated with vemurafenib. J Clin Oncol.
31:e159–e160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robinson GW, Orr BA and Gajjar A: Complete
clinical regression of a BRAF V600E-mutant pediatric glioblastoma
multiforme after BRAF inhibitor therapy. BMC Cancer. 14:2582014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skrypek M, Foreman N, Guillaume D and
Moertel C: Pilomyxoid astrocytoma treated successfully with
vemurafenib. Pediatr Blood Cancer. 61:2099–2100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shih KC, Shastry M, Williams JT, Jelsma
PF, Abram SR, Ayyanar K, Burris HA III and Infante JR: Successful
treatment with dabrafenib (GSK2118436) in a patient with
ganglioglioma. J Clin Oncol. 32:e98–e100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lassaletta A, Guerreiro Stucklin A,
Ramaswamy V, Zapotocky M, McKeown T, Hawkins C, Bouffet E and
Tabori U: Profound clinical and radiological response to BRAF
inhibition in a 2-month-old diencephalic child with
hypothalamic/chiasmatic glioma. Pediatr Blood Cancer. 63:20382016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meletath SK, Pavlick D, Brennan T,
Hamilton R, Chmielecki J, Elvin JA, Palma N, Ross JS, Miller VA,
Stephens PJ, et al: Personalized treatment for a patient with a
BRAF V600E mutation using gabrafenib and a tumor treatment fields
device in a high-grade glioma arising from ganglioglioma. J Natl
Compr Canc Netw. 14:1345–1350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee EQ, Ruland S, LeBoeuf NR, Wen PY and
Santagata S: Successful treatment of a progressive BRAF
V600E-mutated anaplastic pleomorphic xanthoastrocytoma with
vemurafenib monotherapy. J Clin Oncol. 34:e87–e89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Usubalieva A, Pierson CR, Kavran CA,
Huntoon K, Kryvenko ON, Mayer TG, Zhao W, Rock J, Ammirati M,
Puduvalli VK, et al: Primary meningeal pleomorphic
xanthoastrocytoma with anaplastic features: A report of 2 cases,
one with BRAF(V600E) mutation and clinical response to the BRAF
inhibitor dabrafenib. J Neuropathol Exp Neurol. 74:960–969. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chamberlain MC: Salvage therapy with BRAF
inhibitors for recurrent pleomorphic xanthoastrocytoma: A
retrospective case series. J Neurooncol. 114:237–240. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Steinbach JP, Wolburg H, Klumpp A, Probst
H and Weller M: Hypoxia-induced cell death in human malignant
glioma cells: Energy deprivation promotes decoupling of
mitochondrial cytochrome c release from caspase processing and
necrotic cell death. Cell Death Differ. 10:823–832. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Langen KJ, Galldiks N, Hattingen E and
Shah NJ: Advances in neuro-oncology imaging. Nat Rev Neurol.
13:279–289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grossauer S, Koeck K, Murphy NE, Meyers
ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M,
Berger MS, et al: Concurrent MEK targeted therapy prevents MAPK
pathway reactivation during BRAFV600E targeted inhibition in a
novel syngeneic murine glioma model. Oncotarget. 7:75839–75853.
2016. View Article : Google Scholar : PubMed/NCBI
|
